Summary BackgroundTo evaluate the efficacy and safety of intravitreal bevacizumab injections in patients with pigment epithelial detachments (PEDs) secondary to age-related macular degeneration (AMD). Material and methodsIn a retrospective interventional case series, 62 eyes of 61 patients were treated with 1.5 mg bevacizumab intravitreally. Baseline and follow-up visits included best-corrected visual acuity and optical coherence tomography (OCT) examinations. Follow-up visits were performed 1, 3, and 6 months after initial treatment. Morphological effects on PED were quantified by repetitively measuring the highest elevation on two perpendicular OCT cross-sections. If height of PED was increased by 50 microns, or intraretinal fluid appeared or increased, or visual acuity decreased more than 5 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, patients were reinjected. ResultsOn OCT, PED decreased from 346 ± 148 µm at baseline to 241 ± 159 µm (p < 0.001) at 1 month, 227 ± 193 µm (p < 0.001) at 3 months, and 166 ± 170 µm (p < 0.001) at 6 months. Mean best corrected visual acuity (BCVA) increased from 49 ± 18 letters at baseline to 52 ± 21 letters (p = 0.062) at 1 month. However, 3 and 6 months after initial injection mean BCVA returned to baseline levels (3 months: 49 ± 19 letters, p = 0.518; 6 months: 49 ± 20 letters, p = 0.053). On average, patients received 2.5 injections during the observation period of 6 months. Except for one retinal pigment epithelial (RPE) tear no other ocular or systemic adverse events were noticed. Ocular inflammation was not found in any of the investigated patients. ConclusionsThe presented data demonstrate a therapeutic effect of intravitreal bevacizumab in patients with specific classes of pigment epithelial detachments secondary to AMD.
inflammation        0.9999891849475288^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Inflammation          

case series                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Case_series           

optical coherence tomography (OCT)1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Optical_coherence_tomography

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

pigment                       0.9980272313982892^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pigment               

intravitreal                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Intravitreal_administration

efficacy                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Efficacy              

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

PED                           0.999999999761485^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Performance-enhancing_drugs

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

OCT                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Optical_coherence_tomography

Retinopathy                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Retinopathy           

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

microns                       0.9999999999986358^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

PED                           0.999999999761485^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Performance-enhancing_drugs

age-related macular degeneration1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Macular_degeneration  

µm                            0.9999996324409715^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

Morphological                 0.9999999936060249^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Morphology_(biology)  

retinal pigment epithelial    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Retinal_pigment_epithelium

adverse events                0.9941455480173109^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Adverse_effect        

elevation                     0.999964713305003^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Elevation             

ocular                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Human_eye             

epithelial                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Epithelium            

AMD                           0.9999977642426057^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Advanced_Micro_Devices

OCT                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Optical_coherence_tomography

µm                            0.9999996324409715^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

epithelial                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Epithelium            

PED                           0.999999999761485^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Performance-enhancing_drugs

µm                            0.9999996324409715^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

safety                        0.9985398225545741^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Safety                

pigment                       0.9980272313982892^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pigment               

AMD                           0.9999977642426057^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Advanced_Micro_Devices

perpendicular                 0.9957490564212174^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Perpendicular         

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

fluid                         0.9981332027508003^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Viscosity             

intravitreal                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Intravitreal_administration

RPE                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Retinal_pigment_epithelium

µm                            0.9999996324409715^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

